Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).
Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.
Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
German foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.
MIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.
Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.
Paris-based AI-based medical imanging specialist AZmed SA has secured a €15min Series A financing led by Maison Worms, Techstars, and Tempact Ventures.